BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guang MHZ, McCann A, Bianchi G, Zhang L, Dowling P, Bazou D, O'Gorman P, Anderson KC. Overcoming multiple myeloma drug resistance in the era of cancer 'omics'. Leuk Lymphoma 2018;59:542-61. [PMID: 28610537 DOI: 10.1080/10428194.2017.1337115] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Guerrero-Garcia TA, Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Mitsiades C, Anderson KC, Richardson PG. The power of proteasome inhibition in multiple myeloma. Expert Rev Proteomics 2018;15:1033-52. [PMID: 30427223 DOI: 10.1080/14789450.2018.1543595] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
2 Morgan JJ, McAvera RM, Crawford LJ. TRAF6 Silencing Attenuates Multiple Myeloma Cell Adhesion to Bone Marrow Stromal Cells. Int J Mol Sci 2019;20:E702. [PMID: 30736330 DOI: 10.3390/ijms20030702] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
3 Freitas Misakyan MF, Wijeratne EMK, Issa ME, Xu YM, Monteillier A, Gunatilaka AAL, Cuendet M. Structure-Activity Relationships of Withanolides as Antiproliferative Agents for Multiple Myeloma: Comparison of Activity in 2D Models and a 3D Coculture Model. J Nat Prod 2021;84:2321-35. [PMID: 34445874 DOI: 10.1021/acs.jnatprod.1c00446] [Reference Citation Analysis]
4 Ho M, Bianchi G, Anderson KC. Proteomics-inspired precision medicine for treating and understanding multiple myeloma. Expert Rev Precis Med Drug Dev 2020;5:67-85. [PMID: 34414281 DOI: 10.1080/23808993.2020.1732205] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple myeloma. Cancer Treatment Reviews 2018;70:199-208. [DOI: 10.1016/j.ctrv.2018.09.001] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 22.5] [Reference Citation Analysis]
6 Abdi J, Rastgoo N, Chen Y, Chen GA, Chang H. Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells. BMC Cancer 2019;19:975. [PMID: 31638931 DOI: 10.1186/s12885-019-6151-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
7 Li M, Qi L, Xu JB, Zhong LY, Chan S, Chen SN, Shao XR, Zheng LY, Dong ZX, Fang TL, Mai ZY, Li J, Zheng Y, Zhang XD. Methylation of the Promoter Region of the Tight Junction Protein-1 by DNMT1 Induces EMT-like Features in Multiple Myeloma. Mol Ther Oncolytics 2020;19:197-207. [PMID: 33251332 DOI: 10.1016/j.omto.2020.10.004] [Reference Citation Analysis]
8 Ho M, Goh CY, Patel A, Staunton S, O'Connor R, Godeau M, Bianchi G. Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance. Clin Lymphoma Myeloma Leuk 2020;20:e752-68. [PMID: 32651110 DOI: 10.1016/j.clml.2020.05.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
9 Dwivedi S, Rendón-Huerta EP, Ortiz-Navarrete V, Montaño LF. CD38 and Regulation of the Immune Response Cells in Cancer. J Oncol 2021;2021:6630295. [PMID: 33727923 DOI: 10.1155/2021/6630295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Vieira KCO, Silva HRAD, Rocha IPM, Barboza E, Eller LKW. Foodborne pathogens in the omics era. Crit Rev Food Sci Nutr 2021;:1-16. [PMID: 33783282 DOI: 10.1080/10408398.2021.1905603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Tierney C, Bazou D, Majumder MM, Anttila P, Silvennoinen R, Heckman CA, Dowling P, O'Gorman P. Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients. Sci Rep 2021;11:12866. [PMID: 34145309 DOI: 10.1038/s41598-021-90149-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Mohamed A, Collins J, Jiang H, Molendijk J, Stoll T, Torta F, Wenk MR, Bird RJ, Marlton P, Mollee P, Markey KA, Hill MM. Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolome. PLoS One 2020;15:e0227455. [PMID: 31914155 DOI: 10.1371/journal.pone.0227455] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
13 Wang L, Wang X, Wang T, Zhuang Y, Wang G. Multi-omics analysis defines 5-fluorouracil drug resistance in 3D HeLa carcinoma cell model. Bioresour Bioprocess 2021;8. [DOI: 10.1186/s40643-021-00486-z] [Reference Citation Analysis]
14 de Oliveira ÉA, Goding CR, Maria-engler SS. Tumor Models and Cancer Systems Biology for the Investigation of Anticancer Drugs and Resistance Development. In: Schäfer-korting M, Stuchi Maria-engler S, Landsiedel R, editors. Organotypic Models in Drug Development. Cham: Springer International Publishing; 2021. pp. 269-301. [DOI: 10.1007/164_2020_369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Bailly C, Chalopin B, Gouard S, Carlier T, Saëc PR, Marionneau-Lambot S, Moreau P, Touzeau C, Kraeber-Bodere F, Bodet-Milin C, Chérel M. ImmunoPET in Multiple Myeloma-What? So What? Now What? Cancers (Basel) 2020;12:E1467. [PMID: 32512883 DOI: 10.3390/cancers12061467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
16 Ntanasis-Stathopoulos I, Gavriatopoulou M, Terpos E. Antibody therapies for multiple myeloma. Expert Opin Biol Ther 2020;20:295-303. [PMID: 31944131 DOI: 10.1080/14712598.2020.1717464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Harding T, Baughn L, Kumar S, Van Ness B. The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies. Leukemia 2019;33:863-83. [PMID: 30683909 DOI: 10.1038/s41375-018-0362-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
18 Yamamoto L, Amodio N, Gulla A, Anderson KC. Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities. Front Oncol 2020;10:606368. [PMID: 33585226 DOI: 10.3389/fonc.2020.606368] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Saltarella I, Desantis V, Melaccio A, Solimando AG, Lamanuzzi A, Ria R, Storlazzi CT, Mariggiò MA, Vacca A, Frassanito MA. Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. Cells 2020;9:E167. [PMID: 31936617 DOI: 10.3390/cells9010167] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
20 Scherger AK, Al-Maarri M, Maurer HC, Schick M, Maurer S, Öllinger R, Gonzalez-Menendez I, Martella M, Thaler M, Pechloff K, Steiger K, Sander S, Ruland J, Rad R, Quintanilla-Martinez L, Wunderlich FT, Rose-John S, Keller U. Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma. JCI Insight 2019;4:128435. [PMID: 31391340 DOI: 10.1172/jci.insight.128435] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
21 Kim HB, Myung SJ. Clinical implications of the Hippo-YAP pathway in multiple cancer contexts. BMB Rep 2018;51:119-25. [PMID: 29366445 DOI: 10.5483/bmbrep.2018.51.3.018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]